SillaJen Inc Total Assets
SillaJen Inc total assets. Based on the latest financial reports, SillaJen Inc (215600) holds total assets worth ₩124.38 Billion KRW (≈ $84.29 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 215600 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of SillaJen Inc (2015–2024)
Total assets of SillaJen Inc from 2015 to 2024. This chart illustrates how SillaJen Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of SillaJen Inc for real-time trading data and today's change.
SillaJen Inc - Asset Composition Analysis
SillaJen Inc Total Assets Breakdown (December 2024)
SillaJen Inc total assets breakdown as of December 2024. SillaJen Inc's total assets of ₩124.38 Billion consist of 84.6% current assets and 15.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩81.30 Billion | 54.6% |
| Accounts Receivable | ₩596.41 Million | 0.4% |
| Inventory | ₩1.31 Billion | 0.9% |
| Property, Plant & Equipment | ₩1.74 Billion | 1.2% |
| Intangible Assets | ₩19.39 Billion | 13.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how SillaJen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is SillaJen Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SillaJen Inc's current assets represent 84.6% of total assets in 2024, an increase from 41.1% in 2015.
- Cash Position: Cash and equivalents constituted 54.6% of total assets in 2024, up from 36.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 53.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 54.6% of total assets.
SillaJen Inc Competitors by Total Assets
Key competitors of SillaJen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
SillaJen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.80 | 5.99 | 10.01 |
| Quick Ratio | 18.48 | 5.92 | 10.01 |
| Cash Ratio | 0.00 | 4.44 | 0.00 |
| Working Capital | ₩85.41 Billion | ₩116.18 Billion | ₩134.15 Billion |
SillaJen Inc - Advanced Valuation Insights
This section examines the relationship between SillaJen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.06 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 94.2% |
| Total Assets | ₩149.02 Billion |
| Market Capitalization | $184.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values SillaJen Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SillaJen Inc's assets grew by 94.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SillaJen Inc (2015–2024)
The table below shows the annual total assets of SillaJen Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩149.02 Billion ≈ $100.99 Million |
+94.25% |
| 2023-12-31 | ₩76.71 Billion ≈ $51.99 Million |
-25.84% |
| 2022-12-31 | ₩103.45 Billion ≈ $70.10 Million |
-23.28% |
| 2021-12-31 | ₩134.83 Billion ≈ $91.37 Million |
+184.31% |
| 2020-12-31 | ₩47.42 Billion ≈ $32.14 Million |
-75.45% |
| 2018-12-31 | ₩193.19 Billion ≈ $130.92 Million |
-17.77% |
| 2017-12-31 | ₩234.95 Billion ≈ $159.23 Million |
-17.31% |
| 2016-12-31 | ₩284.13 Billion ≈ $192.55 Million |
+85.67% |
| 2015-12-31 | ₩153.03 Billion ≈ $103.70 Million |
-- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more